-

09:45:06 PM

LXRX Stock News

LXRX - Lexicon Pharmaceuticals Inc

09/28/23 9:00 AM

Nasdaq : LXRX

conferencesclinical trial

Lexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023

Lexicon Pharmaceuticals,

RHEA-AI

negative

09/26/23 9:00 AM

Nasdaq : LXRX

conferences

Lexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced

RHEA-AI

negative

09/07/23 4:30 PM

Nasdaq : LXRX

conferences

Lexicon Pharmaceuticals to Participate in the H.C. Wainwright & Co. 25th Annual Global Investment Conference

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the H.C. Wainwright & Co. 25 th Annual Global Investment Conference, taking place September 11-13, 2023. Jeffrey L. Wade, Lexicon’s president and chief

RHEA-AI

neutral

09/07/23 9:00 AM

Nasdaq : LXRX

Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)

Five upcoming scientific presentations will add to the body of evidence supporting the advancement of LX9211 into late-stage development Phase 2b dose optimization study planning underway, with initiation of dosing expected before the end of 2023, and extension to run in parallel with next-stage

RHEA-AI

positive

08/21/23 9:00 AM

Nasdaq : LXRX

conferencesclinical trial

Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that analyses of clinical study results relating to INPEFA™ (sotagliflozin), its recently approved drug for heart

RHEA-AI

negative

08/08/23 9:00 AM

Nasdaq : LXRX

clinical trial

Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure

Post-Hoc Analysis of SOLOIST-WHF Clinical Data Published in Journal of the American College of Cardiology: Heart Failure Risk Reductions of Approximately 50% Demonstrated for Heart Failure Readmissions and for Composite of CV Death and Heart Failure Readmissions at 30- and 90-Days Following

RHEA-AI

negative

08/03/23 4:01 PM

Nasdaq : LXRX

earnings

Lexicon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

INPEFA TM (sotagliflozin) receives FDA approval for the treatment of heart failure INPEFA granted broad label across full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or without diabetes LX9211 moving into late-stage development for the treatment of

RHEA-AI

neutral

07/28/23 4:01 PM

Nasdaq : LXRX

conferencesearnings

Lexicon Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 3, 2023

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2023 financial results on Thursday, August 3 rd, 2023 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m.

RHEA-AI

neutral

07/28/23 8:00 AM

Nasdaq : LXRX

management

Lexicon Elects Diane E. Sullivan to Board of Directors

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Diane E. Sullivan has been elected to its Board

RHEA-AI

neutral

06/23/23 8:45 PM

Nasdaq : LXRX

Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development

First late-stage study will be a Phase 2b dose optimization study, with extension to run in parallel with next-stage Phase 3 studies Feedback obtained from U.S. Food and Drug Administration (FDA) Conference Call and Webcast on Monday, June 26, 2023, at 8:00 am Eastern Time THE WOODLANDS, Texas,

RHEA-AI

very positive

1 2 3 4 5 6 7 8 9 10 Next

LXRX Data

IndustryPharmaceutical Preparation Manufacturing
Websitelexpharma.com
Security nameLexicon Pharmaceuticals Inc
SectorManufacturing
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing

About Lexicon Pharmaceuticals Inc

corporate overview lexicon pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. the genome: our source of discovery we have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. we have integrated a series of recombinant dna and chemistry technologies into a systematic drug discovery and development process. our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. a diverse pipeline of targeted therapies our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indicatio